Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jun 26;14(7):617.
doi: 10.3390/ph14070617.

How to Obtain a High Quality ctDNA in Lymphoma Patients: Preanalytical Tips and Tricks

Estelle Bourbon  1 , Vincent Alcazer  1 , Estelle Cheli  1 , Sarah Huet  1   2 , Pierre Sujobert  1   2
Affiliations
Review

How to Obtain a High Quality ctDNA in Lymphoma Patients: Preanalytical Tips and Tricks

Estelle Bourbon et al. Pharmaceuticals (Basel). .

Abstract

The analysis of circulating tumor DNA (ctDNA) released by tumor cells holds great promise for patients with lymphoma, to refine the diagnostic procedure, clarify the prognosis, monitor the response to treatment, and detect relapses earlier. One of the main challenges of the coming years is to adapt techniques from highly specialized translational teams to routine laboratories as this requires a careful technical and clinical validation, and we have to achieve this as fast as possible to transform a promising biomarker into a routine analysis to have a direct consequence on patient care. Whatever the analytical technology used, the prerequisite is to obtain high yields of ctDNA of optimal quality. In this review, we propose a step-by-step description of the preanalytical process to obtain high-quality ctDNA, emphasizing the technical choices that need to be made and the experimental data that can support these choices.

Keywords: ctDNA; lymphoma; preanalytical.

PubMed Disclaimer

Conflict of interest statement

P.S. and S.H. are members of the OngNGS consortium. The other authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Overview of the ctDNA analysis workflow, with an emphasis on the preanalytical steps that are detailed in this review. When sufficient levels of evidence exist, our recommendations are highlighted in yellow.
See this image and copyright information in PMC

References

    1. Mandel P., Metais P. Nuclear Acids In Human Blood Plasma. C. R. Seances Soc. Biol. Fil. 1948;142:241–243. - PubMed
    1. Jahr S., Hentze H., Englisch S., Hardt D., Fackelmayer F.O., Hesch R.-D., Knippers R. DNA Fragments in the Blood Plasma of Cancer Patients: Quantitations and Evidence for Their Origin from Apoptotic and Necrotic Cells. Cancer Res. 2001;61:1659–1665. - PubMed
    1. Stroun M., Lyautey J., Lederrey C., Olson-Sand A., Anker P. About the Possible Origin and Mechanism of Circulating DNA: Apoptosis and Active DNA Release. Clin. Chim. Acta. 2001;313:139–142. doi: 10.1016/S0009-8981(01)00665-9. - DOI - PubMed
    1. Razavi P., Li B.T., Brown D.N., Jung B., Hubbell E., Shen R., Abida W., Juluru K., Bruijn I.D., Hou C., et al. High-Intensity Sequencing Reveals the Sources of Plasma Circulating Cell-Free DNA Variants. Nat. Med. 2019;25:1928–1937. doi: 10.1038/s41591-019-0652-7. - DOI - PMC - PubMed
    1. Bronkhorst A.J., Ungerer V., Holdenrieder S. The Emerging Role of Cell-Free DNA as a Molecular Marker for Cancer Management. Biomol. Detect. Quantif. 2019;17:100087. doi: 10.1016/j.bdq.2019.100087. - DOI - PMC - PubMed

LinkOut - more resources